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With great interest we read the recent review on familial myelodysplastic syndromes (MDS) published in this journal by Liew and Owen. 1 Besides telomere disorders and familial monosomy 7, the review focused on familial platelet disorder with propensity to myeloid malignancies (FPDMM) and also surveyed syndromic cases of heterozygous loss of chromosome 21q22. To further highlight the clinical diversity of FPDMM and to discuss challenges of the clinical management of patients with germline RUNX1 deficiency, we report here on a patient with a constitutional loss of RUNX1 due to a de novo deletion of 21q22.
Due to chronic, idiopathic thrombocytopenia, retrospectively found to have been present already in childhood, mild anemia and neutropenia, cytogenetic investigations were performed in a 19-year-old patient and displayed a loss of one In view of the early onset of leukemias in 3 out of 12 patients, Liew and Owen hypothesized that the age of leukemic transformation seems to be earlier in patients with deletions in 21q22 than in classical FPDMM. 1 Despite detailed morphological and cytogenetic investigations, there was no evidence of MDS or AML in our 19-year-old patient, although he carries a deletion similar to that seen in the case 2 of non-syndromic thrombocytopenia with myelodysplasia. Moreover, we recently reported on a patient with a RUNX1 mutation displaying a malignant transformation by the age of 13, indicating that in RUNX1 mutation carriers early onset of leukemia is also possible. 3 It is known that secondary genetic alterations are required for the development of leukemia in FPDMM. 3, 4 Possibly, the age of onset depends more on the time and nature of additionally acquired alterations than on the presence of a deletion or mutation of RUNX1.
As pointed out by Liew and Owen 1 , there is fortunately an increased awareness of FPDMM. In addition, the report on the association of RUNX1 mutation with thromobocytopenia, bone marrow blasts, and poor overall survival in patients with MDS 5 will further increase the number of patients with germline RUNX1 deficiency.
While there is an estimated risk of up to 60 % to develop MDS or AML in patients with FPDMM, no surveillance guidelines are available for these patients and their families. In cases presenting with overt leukemia, the clinical management is dictated by the disease and it is broadly accepted that bone marrow transplantations by donors carrying the familial mutation have to be avoided. 6 But what can we offer 
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Figure 1. (A) ETV6/RUNX1 metaphase fluorescence in situ hybridization (FISH).
Metaphase plates of PHA-stimulated peripheral blood cells of the index patient (1) and his parents (2, 3) were investigated using specific probes for RUNX1 (LSI AML1, 
